

## PERSONAL INFORMATION



Replace with First name(s) Surname(s)

📍 Via Ugo Bassi 58-B, Padova 35131, Italy

☎ +390497923277 📠 +393487462671

✉ [carlo.viscomi@unipd.it](mailto:carlo.viscomi@unipd.it)

🌐 <https://www.biomed.unipd.it/ricerca/aree-tematiche/mitochondrial-pathophysiology/mitochondrial-medicine>

Sex M | Date of birth 27/03/1974 | Nationality Italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist
<input type="checkbox"/> Mid-Management Level	<input checked="" type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

## WORK EXPERIENCE

Replace with dates (from - to)

[Add separate entries for each experience. Start from the most recent.]

01/11/2002 – 30/09/2004

**POSTDOCTORAL FELLOW** UNIVERSITÀ DEGLI STUDI DI MILANO, Milan, Italy

16/10/2004 – 15/09/2009

**POSTDOCTORAL FELLOW** IRCCS FOUNDATION NEUROLOGICAL INSTITUTE "C. BESTA", Milan, Italy

16/09/2009 – 31/08/2013

**STAFF SCIENTIST** IRCCS FOUNDATION NEUROLOGICAL INSTITUTE "C. BESTA"

**SENIOR INVESTIGATOR SCIENTIST** UNIVERSITY OF CAMBRIDGE-MRC MITOCHONDRIAL BIOLOGY UNIT, Cambridge, UK

07/01/2020 – CURRENT Padova, Italy

**ASSOCIATE PROFESSOR** UNIVERSITY OF PADOVA, Padova, Italy

## EDUCATION AND TRAINING

Replace with dates (from - to)

01/11/1999 – 16/02/2002 Milano, Italy

**PHD IN PHYSIOLOGICAL SCIENCES**

15/09/1993 – 16/02/1999 Milano, Italy

**LAUREA IN BIOLOGICAL SCIENCES**

## PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s) English: proficient user

## ADDITIONAL INFORMATION

## Publications

Corrà S, Cerutti R, Balmaceda V, Viscomi C, Zeviani M. Double administration of self-complementary AAV9NDUFS4 prevents Leigh disease in *Ndufs4*<sup>-/-</sup> mice. *Brain*. 2022 Oct 21;145(10):3405-3414.

Falabella M, Minczuk M, Hanna MG, Viscomi C, Pitceathly RDS. Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges. *Nat Rev Neurol*. 2022 Nov;18(11):689-698

Silva-Pinheiro P, Pardo-Hernández C, Reyes A, Tilokani L, Mishra A, Cerutti R, Li S, Rozsivalova DH, Valenzuela S, Dogan SA, Peter B, Fernández-Silva P, Trifunovic A, Prudent J, Minczuk M, Bindoff L, Macao B, Zeviani M, Falkenberg M, Viscomi C. DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion. *Nucleic Acids Res*. 2021 May 21;49(9):5230-5248

Luna-Sanchez M, Benincá C, Cerutti R, Brea-Calvo G, Yeates A, Scorrano L, Zeviani M, Viscomi C. Opa1 Overexpression Protects from Early-Onset *Mpv17*<sup>-/-</sup>-Related Mouse Kidney Disease. *Mol Ther*. 2020 Aug 5;28(8):1918-1930.

Garone C, Viscomi C. Towards a therapy for mitochondrial disease: an update. *Biochem Soc Trans*. 2018 Oct 19;46(5):1247-1261.

Torres-Torronteras J, Cabrera-Pérez R, Vila-Julà F, Viscomi C, Cámara Y, Hirano M, Zeviani M, Martí R. Long-Term Sustained Effect of Liver-Targeted Adeno-Associated Virus Gene Therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy. *Hum Gene Ther*. 2018 Jun;29(6):708-718

Di Meo I, Marchet S, Lamperti C, Zeviani M, Viscomi C. AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome. *Gene Ther*. 2017 Oct;24(10):661-667.

Civiletto G, Varanita T, Cerutti R, Gorletta T, Barbaro S, Marchet S, Lamperti C, Viscomi C, Scorrano L, Zeviani M. Opa1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models. *Cell Metab*. 2015 Jun 2;21(6):845-54.

Torres-Torronteras J, Viscomi C, Cabrera-Pérez R, Cámara Y, Di Meo I, Barquinero J, Auricchio A, Pizzorno G, Hirano M, Zeviani M, Martí R. Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. *Mol Ther*. 2014 May;22(5):901-7.

Bottani E, Giordano C, Civiletto G, Di Meo I, Auricchio A, Ciusani E, Marchet S, Lamperti C, d'Amati G, Viscomi C, Zeviani M. AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure. *Mol Ther*. 2014 Jan;22(1):10-7.

Di Meo I, Auricchio A, Lamperti C, Burlina A, Viscomi C, Zeviani M. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. *EMBO Mol Med*. 2012 Sep;4(9):1008-14.

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Padova 24-02-2023